Our proprietary technology is based on polymer encapsulation vesicles which we call Artificial Cell Membranes (“ACMs”). These ACMs are nanoscale vesicles which are made from di-block or tri-block copolymers. For more than 15 years of intensive R&D we have perfected, and patented, techniques of making these ACMs and incorporating payloads within their walls such that these molecules are stable and correctly presented to elicit strong immune responses. We have shown these ACMs to have numerous advantages for the encapsulation of multiple molecule classes such as mRNA, protein, peptides and oligonucleotides.
Our proprietary polymer-based delivery platform enables packaging of mRNA, protein, peptides and/or oligonucleotides, and keeps the payload stable at 4°C. This ACM technology has the potential to revolutionize the delivery to cells and tissues.
At ACM Biolabs we are focused on developing innovative medicines using our targeted delivery platform. Our ACM-001, is an adjuvanted SARS-CoV-2 spike protein (beta variant) vaccine is in Phase 1, dose escalation study comparing intramuscular with intranasal route of administration. We have a preclinical stage personalized cancer vaccine and are building up projects based on mRNA therapeutics.
With all the available functional handles, we believe that our polymer-based vesicles can be functionalized to specifically deliver payloads to target cells and tissues. With this we would have a powerful tool to address a broad range of diseases beyond infectious diseases and cancer.
As a dedicated team combining pharmaceutical industry, biotech, and academic excellence we develop prophylactic and therapeutic vaccines for infectious diseases and therapeutic vaccines for personalized cancer treatment based on our proprietary ACM delivery platform technology.
We believe in challenging the status quo of targeted delivery in medicines and we are revolutionizing the new medicines with ACM platform. We develop these transformative medicines to treat or prevent diseases in a safe and well tolerable way.
Founded in Singapore in 2013, ACM Biolabs has established laboratories for research and early manufacturing activities. ACM Biolabs is well connected in the academic and biotechnology ecosystem.
In 2020 ACM Biosciences was established in Basel, Switzerland to internationalize its development activities. ACM Biosciences leads all clinical and regulatory activities of its pipeline programs. It also coordinates business development discussions with potential partners. ACM Biosciences is a subsidiary of ACM Biolabs.
ACM Biolabs is backed by government bodies, investment companies and strategic corporate investors:
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering (IMRE, A*STAR) and also at Nanyang Technological University).
Pharmacologist and Business Developer with more than 20 years of partnering, R&D, and management experience in pharma. Doctorate in Veterinary Sciences, EMBA from ESSEC Paris & Mannheim Business School. Expertise in business development as Roche VP and Global Head Neuroscience, Ophthalmology, Rare Diseases Partnering, Deal Team Leader and Due Diligence Director. Global Head Safety Pharmacology at Roche Pharmaceuticals. Senior Pharmacologist at Schwarz Pharma AG.
Doctoral Degree (DBA) in the international business, MBA (NTU Singapore), Harvard Certificate in Healthcare Leadership, Post Graduate Diploma in Healthcare Management. Former COO Tan Tock Seng Hospital (SARS period), Ex-CEO NTUC Healthcare, Deputy CEO Richland Logistics (SGX Main board), Deputy CEO, Sensori International (owned OTCBB USA, Hubei Mingkang Pharmaceuticals, China) immediate past member Singapore Parliamentary Committee (Health), past member of Pemandu (Aged care, Kuala Lumpur) and various other senior appointments and board seats in public and private organizations. Adjunct A/P, University of Puthisastra, Cambodia.
Pharmacologist. Vaccines Expert with more than 30 years of experience of R&D.
Doctorat at the Université catholique de Louvain, Belgium. Leading function at GSK, Abivax, NeoVacs, Imcyse, and Amyl Therapeutics. CEO at Vaccibio Consulting.
Dr Pieter Neels is a native of Belgium where he trained as an MD (University of Antwerp, 1985) and was boarded as a general practitioner. In 1997, he joined the Belgian Ministry of Public Health as a senior evaluator of the clinical part of registration files in the field of cardiology, nephrology, endocrinology (diabetes) etc.
In 2001 he was appointed CPMP member. In 2002 he was asked to take over all Belgian central vaccine rapporteur ships. He was elected vice-chair of Vaccine Working Party, a CHMP workgroup for vaccines for discussion on development and evaluation of registration files for vaccines until June 2013.
WHO has asked Dr Neels to attend many meetings on vaccine development all over the world in order to share the EU regulatory requirements/competence in vaccinology.
Dr Neels is also a member of the worldwide network on vaccine promotion as he is asked to attend the ADVAC course (Foundation Mérieux) and the IABS conferences.
In 2013 Dr Neels was nominated associate Professor at the Namur University for a course in Vaccinology, he retired in 2020.
In June 2013 Dr Neels stepped down from the CHMP and left the Belgian Federal Agency to start his own consultancy company “Vaccine-Advice” in order to be able to support vaccine development in a more efficacious way.
In 2014 Dr Neels was elected board member of IABS-EU and in 2016 he accepted to chair the Human Vaccine Committee of IABS.
Founder of the Erber Group, an Austrian animal nutrition company (now part of DSM), which consists of more than 50 affiliates in all continents. He is also founder of the SAN Pacific Investments Group. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs’ Board of Directors.
Sang Bin is currently the managing director of Ritz Venture Capital, a Singapore based family fund that focuses in supporting early-stage companies. He has over 30 years of experience in venture investments as well as mentorship within the academic community. With his background in engineering and business, he is a strong supporter of applying cutting edge technology and cultivating talents to address some of the key challenges in the world in the near future.
Ex-CEO of Protein Sciences, developed first FDA approved protein flu vaccine. Bought by Sanofi for US$650 million and milestones.
Medical Director at Swiss Tropical and Public Health Institute. Professor at University of Basel & University of Oxford.
Professor & Chair, Clinical Immunology, University of Zurich, Director, Department of Immunology, University Hospital Zurich.
30 years of executive, director, investor and mentor experience in the life science industry.
PhD. Managed the Micro- and Nano-systems group of 50 R&D staff in the Singapore research institute where the polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. Has worked with Dr Nallani on ACM since 2011.
Katherine Schultheis joined ACM Biosciences in 2022 as Head of Discovery Research with a strong background of preclinical development of DNA based vaccines and immunotherapeutics. Katherine has more than 10 years of academic and corporate research experience in the fields of infectious diseases, autoimmunity and oncology. She was heading a research team at Inovio Pharmaceuticals in San Diego, California, before moving back to the greater Basel area in 2021. Katherine obtained her Master’s level degree in Biochemistry from University of Potsdam, Germany.
Yvonne has over 30 years’ experience in the biopharmaceutical industry and significant technical, commercial and project management expertise in the development and commercialisation of oral and parenteral small molecule and biological products.
Prior to joining Cilatus, Yvonne was the Vice President of Technical Operations Project Management and Strategy at Horizon Pharma, overseeing all project managers responsible for managing tech transfers for both a number of small molecule oral products and biologics in late-stage development and commercial settings. She was instrumental in developing project planning systems, processes and tools in constantly changing pharmaceutical development and operational environments.
At Alkermes Pharma she was the Senior Director, Head of Project Management, responsible for the planning, budgeting and tracking of development and commercial product support projects at the Athlone facility, Ireland. At Elan Drug Technologies, she held the position of Senior Director, Head of Project Management, and she was responsible for planning, budgeting and tracking of development and commercial product support projects across 3 locations in Ireland and the US.
Yvonne holds a BSc. degree in Biochemistry and Chemistry, and PhD in Endocrinology from University College Dublin.
Since joining Cilatus, Yvonne has been acting as the CMC team leader for a small molecule for a client and she has been engaged in CDMO/CMO searches. For ACM Biosciences Yvonne is the CMC Project Lead.
Daniel Speiser is a physician-scientist who graduated in 1982 at the University of Zürich, Switzerland.
Subsequently he specialized in basic and clinical immunology at the Universities of Geneva and Toronto. Over many years he was pioneering clinical cancer immunotherapy and translational research at the University Hospital of Lausanne. He continues promoting clinical cancer immunotherapy development and research at the Universities of Lausanne and Bern, in collaboration with academic and industrial specialists.
Master’s Degree in Humanities at University of Stuttgart (Germany). Master’s Degree (MAS) in Marketing and Business Development at University of Basel (CH). Project Manager with more than 20-year experience in R&D pharma and art business.
Research associate at ACM Biolabs. Obtained a diploma in Molecular Biotechnology in 2012 and Bachelor’s degree in Biological Sciences in 2019 at the Nanyang Technological University.
Research associate in ACM Biolabs. Obtained a diploma in Chemical and Biomolecular Engineering in 2015 and Bachelor’s degree with Honours in Chemistry in 2019 at the National University of Singapore.
Senior research associate at ACM Biolabs. Obtained a bachelor’s degree in Chemistry and Biological Chemistry in 2019 at the Nanyang Technological University.
Jian Hang Lam holds a Ph.D. from the Yong Loo Lin School of Medicine, National University of Singapore. He was trained in pre-clinical dengue vaccine development and gained experience in virology and immunology, with special focus on investigating correlates of protection.
Dr. Liu received her PhD in chemical and biomolecular engineering from National University of Singapore (NUS). She has more than 15 years of research and development experience in Biomedical science and Bioengineering. She has generated 5 patents and 42 papers in reputable journals including Nature communications and Advanced Materials.
Ser Yue Loo is a Senior Scientist at ACM Biolabs. Prior to joining ACM Biolabs, Ser Yue carried out her postdoctoral fellowship at Genome Institute of Singapore, where she conducted research on therapeutics for treatment of triple negative breast cancer. Her work led to the successful translation from bench to bedside with the initiation of a clinical trial BEXMET in National Cancer Centre Singapore.
Loo Ser Yue obtained her PhD from Yong Loo Lin School of Medicine at National University of Singapore in 2014.
A reliable professional with excellent interpersonal, planning and customer service skills to ensure effective operations in the organisation. With 15 years of experience in providing administration, accounts, payroll and program management in the education industry such as SIM, National University of Singapore and Singapore University of Social Sciences.
I joined ACM Biolabs in November 2019 as an Accountant. Prior to this, I worked in a few organisations holding roles as accountant and financial controller . Other than overseeing the regular operation s of a n accounts and finance departme nt, my work typically involve d enhancement and improvement in internal finan c ial systems. A s a manager in Mitsubishi Electric Singapore , I was heavily involved in the development and establishment p rocurement system for the As ia Procurement Centre, using SAP. To better manage cost centres, I helped in the development and establishment of shared services centr e. At Kn owledge Universe , I was involved in the acquisition and merger of local SMEs which resulted in some 700 teachers. My involvement include d preparation and handling of due diligence and legal clearance , and the assimilation of a new parent and siblings at the operational ground level . Arising from the merger of various entities, I lead the integration of the financial systems and establishment of Oracle financial system . Business in a n interestingly challeng ing interplay of human intellects, o pportunities and res ources , facilitated by i ts internal systems . I hope to continue to play a part in some of thes e areas in ACM’s journey into the future.
Henry Cheng is an accountancy graduate from NUS (Singapore), holds an MBA (Glasgow University) and CIMA (UK). He has worked with US multinational companies like Rockwell International, Becton Dickinson and RR Donnelley & Sons. Besides manufacturing, he has also worked in the logistics, Online cum Retail business sectors. He used to cover the Asia Pacific region, including involvement in several start-ups.
Experienced Researcher in the areas of Pharmaceutical Formulations and Preclinical Product Development. Doctorate in Chemical Engineering from the University of Kentucky with Post-doctoral experiences from New York University and Singapore-MIT Alliance for Research & Technology, Singapore.
Devendra obtained his bachelor’s degree in Biotechnology from Vellore Institute of Technology and master’s degree in Biotechnology and Biochemical engineering from Indian Institute of Technology. After a brief working experience in India, Devendra decided to pursue higher study and joined Nanyang Technological University, Singapore. In his PhD, he gained significant experience in protein biochemistry. Devendra continued his academic career at NTU as a Post-Doc to study Protein-protein interaction networks.
Gaurav joined ACM Biolabs in 2021, after completing his PhD research in the field of point-of-care diagnostics from the School of Material Science and Engineering at NTU.
Vishwa Prasad Aitha is an accomplished scientist with over 20 years of experience in polymer development and commercialization for well-established companies such as Evonik AG, BASF AG, Institute of Chemical and Engineering Sciences and Mitsui Chemicals, Inc.
He has a proven track record of success developing commercial products from concepts and has demonstrated experience in spearheading large and complex R&D projects throughout its entire lifecycle.
In 1999, Prasad had received his PhD from the National Chemical Laboratory, Pune, India.
Studied Veterinary Microbiology from the Royal Veterinary College, London. Spent more than a decade working in a government animal disease research centre in East Malaysia as a bacteriologist supporting field veterinarians in their diagnosis of livestock diseases. Then she moved on to work in an MNC based in Singapore and spent another 17 years for an animal health related job.
Ameet is working closely with the dynamic & talented Technology Development team on our lead programme; his key focus is to translate the Polymersome platform technology from preclinical to clinical development.
Ameet brings with him breadth of experience in discovery, development, and commercial manufacturing of novel therapeutics in Global pharma cos, such as Novartis and MSD. Over last few years Ameet has been passionately working with the early-stage venture backed biopharma in UK, Europe, and APAC region to create value to the development programme.
We are looking for highly motivated specialists – take a look at our career offers
* Intramuscular and intranasal delivery
We are currently building a high quality and motivated team to bring our COVID 19 vaccine through clinical trials. We are particularly interested in hearing from candidates who specialize in vaccine development, have liposomal or polymersomal formulation experience. Interested applicants should please forward their resumé / CV to firstname.lastname@example.org